Abstract:Tumor immunotherapy is often hindered by unresponsive cold tumor microenvironments (TME). Although Salmonella-based immunotherapy has shown potential in overcoming these cold immune environments, safety concerns remain. Our study introduces a genetically reprogrammed Salmonella typhimurium strain (OASL) with a dual safety lock to enhance safety and modify immunosuppressive TME, sensitizing tumors to immunotherapies. We propose using OASL to alter the cold TME and locally release therapeutic cargos such as PDL1 nanobodies and tumor-specific neoantigen peptides identified through bioinformatic algorithms, activating immune cells within the tumor while minimizing side effects. We selected YB1, an obligate anaerobic Salmonella strain that thrives in hypoxic environments, as our base strain and incorporated a self-lysis genetic circuit for controlled bacterial growth and cargo release upon reaching a specific population density within the tumor core. We assembled and evaluated the self-lysis gene circuit in vitro, documenting the event using an optical density (OD) reader and confirming OASL's ability to express genetic cargos through western blot analysis. We then investigated OASL's therapeutic effect in vivo and characterized TME changes using flow cytometry and immunohistochemistry staining. Our results indicate that OASL undergoes lysis and releases cargos upon reaching a specific population density in vitro. Additionally, OASL-delivered neoantigen peptides elicited a tumor-specific immune response in vivo. OASL also demonstrated the capacity to modify the TME and restore sensitivity to PDL1 in previously unresponsive tumors, enhancing therapeutic effects. Citation Format: Yige He, Jiandong Huang. Leveraging an obligate anaerobic salmonella strain for targeted cargo delivery in the tumor microenvironment to restore immunotherapy sensitivity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6666.

Genetically Modified "obligate" Anaerobic Salmonella Typhimurium As a Therapeutic Strategy for Neuroblastoma

Treatment of Neuroblastoma with an Engineered "Obligate" Anaerobic Salmonella typhimurium Strain YB1.

Oral Delivery of Tumor‐targeting Salmonella Exhibits Promising Therapeutic Efficacy and Low Toxicity

Macrophage-mediated tumor-targeted delivery of engineered Salmonella typhimurium VNP20009 in anti-PD1 therapy against melanoma

Abstract 6666: Leveraging an obligate anaerobic salmonella strain for targeted cargo delivery in the tumor microenvironment to restore immunotherapy sensitivity

Local application of bacteria improves safety of Salmonella -mediated tumor therapy and retains advantages of systemic infection

Salmonella-mediated tumor-targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model.

The treatment of tumor-bearing mice with auxotrophy Salmonella typhimurium

Salmonella promote T cell-mediated anti-tumor immuno-therapy

Synergistic Antitumor Effect of Combined Radiotherapy and Engineered Salmonella typhimurium in an Intracranial Sarcoma Mouse Model

Oral Administration of A Live Attenuated Salmonella Containing Murine Il-12, Gm-Csf Gene Leads to Tumor Regression and Prolongation of Survival in Mice

Repolarizing neutrophils via MnO2 nanoparticle-activated STING pathway enhances Salmonella-mediated tumor immunotherapy

Camouflaging attenuated Salmonella by cryo-shocked macrophages for tumor-targeted therapy

AttenuatedSalmonella VNP20009 Mutant(δhtra) is a Promising Candidate for Bacteria-Mediated Tumour Therapy in Hosts with TNFR1 Deficiency

Proteomic Screening of Anaerobically Regulated Promoters from Salmonella and Its Antitumor Applications.

“Trojan Horse” Salmonella Enabling Tumor Homing of Silver Nanoparticles via Neutrophil Infiltration for Synergistic Tumor Therapy and Enhanced Biosafety

Tumor-targeting Salmonella typhimurium A1-R overcomes nab-paclitaxel resistance in a cervical cancer PDOX mouse model

Reprogramming the tumor immune microenvironment using engineered dual-drug loaded Salmonella

In situ immunomodulation of tumors with biosynthetic bacteria promote anti-tumor immunity

Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin

Engineered Salmonella Inhibits GPX4 Expression and Induces Ferroptosis to Suppress Glioma Growth in Vitro and in Vivo.